Josh Allen

Company: Oncoceutics
Job title: Chief Scientific Officer
Seminars:
Targeting DRD2 and ClpP in High Grade Glioma with ONC201: Emerging Clinical Results and Future Trials 12:45 pm
Review DRD2 as therapeutic target in oncology Update on the latest ONC201 clinical results in H3 K27M-mutant gliomas Overview of ONC201 in other CNS tumors and emerging trialsRead more
day: Day Two